PlainRecalls
FDA Drug Moderate Class II Ongoing

Ranitidine Tablets, USP 150 mg a).60-count bottles (NDC 65162-253-06) , b).100-count bottles (NDC 65162-253-10), c).180-count bottles (NDC 65162-253-18), d).500-count bottles (NDC 65162-253-50) and e)1000-count bottles (NDC 65162-253-11).

Reported: December 18, 2019 Initiated: November 22, 2019 #D-0612-2020

Product Description

Ranitidine Tablets, USP 150 mg a).60-count bottles (NDC 65162-253-06) , b).100-count bottles (NDC 65162-253-10), c).180-count bottles (NDC 65162-253-18), d).500-count bottles (NDC 65162-253-50) and e)1000-count bottles (NDC 65162-253-11).

Reason for Recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Details

Units Affected
N/A
Distribution
Product was distributed throughout the United States.
Location
Brookhaven, NY

Frequently Asked Questions

What product was recalled?
Ranitidine Tablets, USP 150 mg a).60-count bottles (NDC 65162-253-06) , b).100-count bottles (NDC 65162-253-10), c).180-count bottles (NDC 65162-253-18), d).500-count bottles (NDC 65162-253-50) and e)1000-count bottles (NDC 65162-253-11).. Recalled by Amneal Pharmaceuticals, Inc.. Units affected: N/A.
Why was this product recalled?
CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API
Which agency issued this recall?
This recall was issued by the FDA Drug on December 18, 2019. Severity: Moderate. Recall number: D-0612-2020.